These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 7478541)
1. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Eliopoulos AG; Kerr DJ; Herod J; Hodgkins L; Krajewski S; Reed JC; Young LS Oncogene; 1995 Oct; 11(7):1217-28. PubMed ID: 7478541 [TBL] [Abstract][Full Text] [Related]
2. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971 [TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Herod JJ; Eliopoulos AG; Warwick J; Niedobitek G; Young LS; Kerr DJ Cancer Res; 1996 May; 56(9):2178-84. PubMed ID: 8616869 [TBL] [Abstract][Full Text] [Related]
4. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Jones NA; Turner J; McIlwrath AJ; Brown R; Dive C Mol Pharmacol; 1998 May; 53(5):819-26. PubMed ID: 9584207 [TBL] [Abstract][Full Text] [Related]
5. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822 [TBL] [Abstract][Full Text] [Related]
6. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Henkels KM; Turchi JJ Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248 [TBL] [Abstract][Full Text] [Related]
7. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas. Song K; Li Z; Seth P; Cowan KH; Sinha BK Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008 [TBL] [Abstract][Full Text] [Related]
8. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells. Chang FL; Ling YF; Lai MD Anticancer Res; 2000; 20(1A):329-36. PubMed ID: 10769676 [TBL] [Abstract][Full Text] [Related]
9. Pro-apoptotic treatment with an adenovirus encoding Bax enhances the effect of chemotherapy in ovarian cancer. Xiang J; Gómez-Navarro J; Arafat W; Liu B; Barker SD; Alvarez RD; Siegal GP; Curiel DT J Gene Med; 2000; 2(2):97-106. PubMed ID: 10809143 [TBL] [Abstract][Full Text] [Related]
10. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin. Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878 [TBL] [Abstract][Full Text] [Related]
11. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy. Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753 [TBL] [Abstract][Full Text] [Related]
12. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Debernardis D; Siré EG; De Feudis P; Vikhanskaya F; Valenti M; Russo P; Parodi S; D'Incalci M; Broggini M Cancer Res; 1997 Mar; 57(5):870-4. PubMed ID: 9041188 [TBL] [Abstract][Full Text] [Related]
13. [Role of apoptosis-associated genes and caspase-3 in cisplatin-resistant human ovarian cancer cell lines]. Yang XK; Xing H; Zheng F; Gao QL; Wang W; Lu YP; Ma D Zhonghua Fu Chan Ke Za Zhi; 2003 Mar; 38(3):158-61. PubMed ID: 12816691 [TBL] [Abstract][Full Text] [Related]
14. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Liu JR; Fletcher B; Page C; Hu C; Nunez G; Baker V Gynecol Oncol; 1998 Sep; 70(3):398-403. PubMed ID: 9790794 [TBL] [Abstract][Full Text] [Related]
15. Role of p53 in G2/M cell cycle arrest and apoptosis in response to gamma-irradiation in ovarian carcinoma cell lines. Concin N; Stimpfl M; Zeillinger C; Wolff U; Hefler L; Sedlak J; Leodolter S; Zeillinger R Int J Oncol; 2003 Jan; 22(1):51-7. PubMed ID: 12469184 [TBL] [Abstract][Full Text] [Related]
16. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models. Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289 [TBL] [Abstract][Full Text] [Related]
17. Acquired alkylating drug resistance of a human ovarian carcinoma cell line is unaffected by altered levels of pro- and anti-apoptotic proteins. Roy G; Horton JK; Roy R; Denning T; Mitra S; Boldogh I Oncogene; 2000 Jan; 19(1):141-50. PubMed ID: 10644989 [TBL] [Abstract][Full Text] [Related]
18. Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Wosikowski K; Regis JT; Robey RW; Alvarez M; Buters JT; Gudas JM; Bates SE Cell Growth Differ; 1995 Nov; 6(11):1395-403. PubMed ID: 8562478 [TBL] [Abstract][Full Text] [Related]
19. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Anthoney DA; McIlwrath AJ; Gallagher WM; Edlin AR; Brown R Cancer Res; 1996 Mar; 56(6):1374-81. PubMed ID: 8640828 [TBL] [Abstract][Full Text] [Related]